Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2004

View Archived Issues

Esperion Therapeutics plans to develop therapies based on PPARdelta agonists

Helsinn and Taiho sign an agreement for palonosetron

Interim data on the effects of GTI-2040 and capecitabine in advanced renal cell cancer

Once monthly ibandronate found effective in the management of osteoporosis

New phase II results described for NGD-2000-1 in asthma

OyaGen, a new company to develop a novel class of HIV drugs

Sucampo completes a new phase III clinical trial with SPI-0211 in constipation

Good safety and pharmacokinetic data reported for XP-13512 in healthy volunteers

Novel antibacterial macrolides under investigation at Janssen

Vertex claims JAK/CDK2 inhibitors for allergic and immune disorders

Merck presents new inhibitors of B. anthracis lethal factor

Galderma describes two series of RAR antagonists for dermatological disorders

AstraZeneca presents new CRTh2 modulators with utility in respiratory disorders

New antibacterial PDF inhibitors covered by GSK patent

NeuroSearch team describes dual nAChR/monoamine transporter modulators

Xenon Genetics selects clinical candidates for metabolic syndrome program

Cytos' Immunodrug for nicotine addiction enters phase II trial in smokers

Women's Health Connecticut adopts use of Digene's DNAwithPap Test

LUMC and OctoPlus to evaluate new drug for chronic middle ear infection

Watson launches generic sustained-release bupropion hydrochloride

Phase III eflornithine trial in superficial bladder cancer discontinued

PTC Therapeutics raises funds to support development of PTC-124

CP-690550 demonstrates immunosuppressive potential in mice

Fujisawa, AtheroGenics to jointly develop transplant rejection treatment AGI-1096

Revenues increase at Genzyme

CytRx funds RNA interference research for CMV disease treatment

WAY-135433 promotes HDL cholesterol increase

AFP-168, a novel ocular hypotensive candidate

Academic researchers discover novel SERM with CNS effects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...